FPC Investment Advisory Inc. Buys Shares of 26,456 Fate Therapeutics, Inc. (NASDAQ:FATE)

FPC Investment Advisory Inc. acquired a new stake in Fate Therapeutics, Inc. (NASDAQ:FATE) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 26,456 shares of the biopharmaceutical company’s stock, valued at approximately $44,000.

Other institutional investors have also modified their holdings of the company. JPMorgan Chase & Co. grew its stake in shares of Fate Therapeutics by 18.2% in the third quarter. JPMorgan Chase & Co. now owns 1,837,304 shares of the biopharmaceutical company’s stock valued at $6,431,000 after buying an additional 283,080 shares in the last quarter. Barclays PLC grew its stake in shares of Fate Therapeutics by 245.3% in the third quarter. Barclays PLC now owns 424,277 shares of the biopharmaceutical company’s stock valued at $1,485,000 after buying an additional 301,389 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Fate Therapeutics by 30.6% in the fourth quarter. SG Americas Securities LLC now owns 44,874 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 10,511 shares in the last quarter. Walleye Capital LLC grew its stake in shares of Fate Therapeutics by 263.5% in the third quarter. Walleye Capital LLC now owns 67,609 shares of the biopharmaceutical company’s stock valued at $237,000 after buying an additional 49,009 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Fate Therapeutics by 0.5% in the third quarter. Geode Capital Management LLC now owns 2,258,246 shares of the biopharmaceutical company’s stock valued at $7,905,000 after buying an additional 10,863 shares in the last quarter. 97.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

FATE has been the subject of a number of research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of Fate Therapeutics in a research note on Tuesday, November 19th. Wedbush reissued a “neutral” rating and set a $5.00 target price on shares of Fate Therapeutics in a research note on Tuesday, November 12th. Finally, Bank of America raised Fate Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Fate Therapeutics presently has an average rating of “Hold” and a consensus price target of $6.75.

Insider Transactions at Fate Therapeutics

In other Fate Therapeutics news, Director Redmile Group, Llc acquired 397,964 shares of the stock in a transaction dated Friday, December 20th. The stock was acquired at an average cost of $1.68 per share, with a total value of $668,579.52. Following the transaction, the director now owns 12,884,277 shares in the company, valued at $21,645,585.36. The trade was a 3.19 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.00% of the company’s stock.

Fate Therapeutics Stock Performance

NASDAQ:FATE opened at $1.42 on Friday. The stock has a 50-day simple moving average of $1.49 and a 200-day simple moving average of $2.53. The stock has a market cap of $161.72 million, a P/E ratio of -0.86 and a beta of 2.02. Fate Therapeutics, Inc. has a 1 year low of $1.04 and a 1 year high of $8.83.

Fate Therapeutics Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.